Correction: Expert Opinions on the Management of Hemophilia A in India: The Role of Emicizumab
Naresh Gupta, Anupam Dutta, Bilal Ahmed, Cecil R Ross, Chandrakala S, Gerard Dolan, M J John, Nita Radhakrishnan, Sunita Aggarwal, Tulika Seth, Varun Kaul, Vijay Shah
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsBusiness Process Modeling and Analysis · Distributed systems and fault tolerance · Advanced Software Engineering Methodologies
This article has been corrected by the Editor-in-Chief to remove or amend four statements referring to emicizumab as an on-demand therapy. Emicizumab is not approved as an on-demand therapy, therefore the following corrections have been made to ensure scientific accuracy:
The following statements have been removed:
"On-demand emicizumab was more cost-effective than prophylactic emicizumab in non-inhibitor patients. However, in inhibitor patients, prophylactic emicizumab is cost-effective."
"Patients willing to pay only for on-demand emicizumab may lose out on its effectiveness in reducing joint disease. Until gene therapy becomes a reality, the disability caused by HA must be controlled using emicizumab.
The following statements have been revised to remove the reference to "on-demand" therapy:
"However, modeling studies have reported the cost-effectiveness of emicizumab prophylaxis over FVIII prophylaxis and over emicizumab on-demand treatment, low-dose prophylaxis, intermediate-dose prophylaxis, and high-dose prophylaxis [8,57]."
"The benefits of emicizumab override the cost of the drug. It is effective as a prophylactic, on-demand, and maintenance therapy in patients of all ages and patients with systemic diseases such as hepatic disease, and renal problems."